Logo image
Home Academic units
Sign in
Drug targets evolve, and so should the methods
Journal article   Open access   Peer reviewed

Drug targets evolve, and so should the methods

Christopher Wilson, Roman V Agafonov and Dorothee Kern
Molecular & cellular oncology, Vol.3(4), pp.e1046580-e1046580
07/03/2016
PMCID: PMC4972104
PMID: 27652309

Abstract

protein kinases Cancer drugs Gleevec Evolution Drug Design
Design of specific kinase inhibitors is an appealing approach for developing new anticancer treatments. However, only a few success stories have been reported to date. Here we demonstrate how the combination of old-fashioned and new biophysical tools together with recent advances in genomics and molecular evolution can aid in overcoming existing limitations.
url
https://doi.org/10.1080/23723556.2015.1046580View
Published (Version of record) Open

Metrics

24 Record Views

Details